SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001213900-23-075818
Filing Date
2023-09-12
Accepted
2023-09-11 18:23:03
Documents
2

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea185019-13dhanmi_aptose.htm SC 13D 55471
2 SUBSCRIPTION AGREEMENT, DATED AS OF SEPTEMBER 6, 2023, BY AND BETWEEN THE REPORT ea185019ex99-1_aptosebio.htm EX-99.1 327046
  Complete submission text file 0001213900-23-075818.txt   384357
Mailing Address 251 CONSUMERS ROAD SUITE 1105 TORONTO A6 M2J 4R3
Business Address 251 CONSUMERS ROAD SUITE 1105 TORONTO A6 M2J 4R3 647-479-9828
Aptose Biosciences Inc. (Subject) CIK: 0000882361 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-49893 | Film No.: 231248679
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 14, WIRYESEONG-DAERO, SONGPA-GU SEOUL M5 05545
Business Address 14, WIRYESEONG-DAERO, SONGPA-GU SEOUL M5 05545 8224108796
Hanmi Pharmaceutical Co., Ltd. (Filed by) CIK: 0001904921 (see all company filings)

IRS No.: 000000000 | State of Incorp.: M5 | Fiscal Year End: 1231
Type: SC 13D